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CRL4CDT2 Targets CHK1 for PCNA-Independent Destruction
Jiwon Huh,a,b Helen Piwnica-Wormsa,b,c
Department of Cell Biology and Physiology,a BRIGHT Institute,b and Department of Medicine,c Washington University School of Medicine, St. Louis, Missouri, USA
CDT2 targets proteins involved in replication licensing (CDT1), cell cycle control (p21), and chromatin modification (SET8) for
destruction by the CUL4-based E3 ligase (CRL4). CRL4CDT2 recruits these substrates through interactions with chromatin-
bound PCNA and ubiquitinates them exclusively on chromatin. Rereplication and G2 cell cycle arrest are observed in CDT2-
depleted cells. The rereplication phenotype has been attributed to an inability to destroy CDT1, but the molecular target impor-
tant for G2 cell cycle arrest in CDT2-depleted cells has not been identified. Here we identify CHK1 as a novel CRL4
CDT2 substrate
and demonstrate that CHK1 activity is required for maintaining G2 arrest in CDT2-depleted cells. We demonstrate that
CRL4CDT2 targets the activated form of CHK1 for destruction in the nucleoplasm rather than on chromatin and that this occurs
in a PCNA-independent manner. Although both CRL1 and CRL4 ubiquitinate CHK1, we report that they bind CHK1 in distinct
cellular compartments. Our study provides insight into how elevated CDT2 expression levels may provide tumors with a prolif-
erative advantage.
The CHK1 protein kinase maintains genome integrity in nor-mal cycling cells and in cells exposed to replication or geno-
toxic stress (1, 2). Replication stress that occurs during the normal
course of DNA replication or following exposure to antimetabo-
lites or certain DNA-damaging agents generates single-stranded
DNA (ssDNA). ssDNA is also generated in the course of DNA
repair and double-strand break (DSB) end resection. The CHK1
signaling pathway is engaged by checkpoints that detect ssDNA.
Replication protein A (RPA) coats ssDNA, thereby recruiting a
DNA damage-sensing complex consisting of ATR (ataxia telangi-
ectasia- and RAD3-related protein) and ATRIP (ATR-interacting
protein) (3, 4). The ATR/ATRIP module, together with RAD17
and the 9-1-1 complex, activates CHK1 in a claspin-dependent
manner on chromatin (5–9). ATR phosphorylates CHK1 on ser-
ine 317 (S317) and serine 345 (S345), which in turn activates
CHK1 by facilitating autophosphorylation on S296 (10–13). Ac-
tivated CHK1 is then released from chromatin and phosphoryl-
ates downstream effectors to temporarily halt cell cycle progres-
sion, stabilize stalled replication forks, and regulate DNA repair
(4, 14).
ATR-mediated phosphorylation activates CHK1 and also pro-
motes its ubiquitin-mediated proteolysis by facilitating interac-
tions with two distinct E3 ubiquitin ligases that employ CUL1 and
CUL4A (15–17). These cullin proteins function as scaffolds in
multisubunit complexes known as cullin-RING ligases (CRLs)
(18). CRLs recruit substrates via adaptor proteins specific for each
cullin scaffold. CRL1 employs SKP1 (S-phase kinase-associated
protein 1), and CRL4 utilizes DDB1 (damaged DNA binding pro-
tein 1). Cullin-adaptor complexes often require additional sub-
strate receptors to recruit and ubiquitinate target proteins. Sub-
strate receptors provide E3 ubiquitin ligases with the specificity
required to target their diverse repertoire of cellular substrates for
ubiquitination. While F-box proteins recruit substrates to CRL1,
CRL4 often recruits its substrates via DCAFs (DDB1- and CUL4-
associated factors) (19–21). More than a hundred DCAFs and
putative DCAF proteins have been identified based on character-
istic motifs, including WD40 repeats, WDXR motifs, and DDB
boxes (19–23). The DCAF protein CDT2 recognizes substrates
containing a specialized PCNA (proliferating cell nuclear antigen)
interaction protein motif (PIP box) called a PIP degron (24).
Chromatin-bound PCNA mediates the recruitment of PIP de-
gron-containing substrates to CRL4CDT2 (24).
The F-box protein FBX6 facilitates interactions between CHK1
and CRL1 (16), but the substrate receptor mediating interactions
between CHK1 and CRL4 has not been identified. Furthermore, it
is unclear why two distinct E3 ubiquitin ligases mediate CHK1
degradation. Here we demonstrate that CDT2 targets the acti-
vated form of CHK1 to CRL4 using a noncanonical mechanism
and that CHK1 stability is regulated in distinct cellular compart-
ments by CRL1FBX6 and CRL4CDT2. We also demonstrate that
CHK1 kinase activity is essential for the maintenance of G2 cell
cycle arrest in CDT2-depleted cells.
MATERIALS AND METHODS
Cell culture, antibodies, and reagents. HeLa cells were grown in Dulbec-
co’s modified Eagle’s medium (DMEM) (Life Technologies) supple-
mented with 10% bovine growth serum, L-glutamine, and penicillin-
streptomycin. HeLa Tet-on cells (Clontech) were grown in DMEM
supplemented with 10% Tet system-approved fetal bovine serum (Clon-
tech), L-glutamine, penicillin-streptomycin, and 100 g/ml Geneticin
(Life Technologies). 293T cells were grown in DMEM supplemented with
10% fetal bovine serum and L-glutamine. The following antibodies were
purchased: CHK1 (G-4), CUL1 (H-213), CDT2 (B-8), Myc (9E10),
PCNA (PC10), SKP1, and FBX6 (7B11) antibodies were purchased from
Santa Cruz Biotechnology; actin, Flag (M2), and claspin antibodies were
purchased from Sigma; CUL4 and CDT1 antibodies were purchased from
Bethyl Laboratories; CUL4A antibody was purchased from Rockland Im-
munochemicals; V5, CDT2, DDB1, and tubulin antibodies were pur-
chased from Abcam; CHK1 phospho-S296 (pS296) antibody was pur-
chased from Epitomics; CHK1 phospho-S345 (pS345) (133D3)
antibody was purchased from Cell Signaling; -catenin and ORC2
antibodies were purchased from BD Biosciences; and SET8 antibody
was purchased from Millipore. The affinity-purified anti-CHK1 anti-
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body was described previously (15). Hydroxyurea (HU), MG132 (Z-
Leu-Leu-Leu-al), and cycloheximide (CHX) were purchased from
Sigma, doxycycline was purchased from Clontech, and AZD7762
(AZD) was purchased from Axon Medchem. Cells were irradiated by
using a UV Stratalinker 2400 instrument (Stratagene).
Plasmid andRNAi transfections.Plasmids expressing 3Flag-CHK1
and V5-CUL4A were described previously (15), and a plasmid expressing
V5-CUL1 was similarly generated by Van Leung-Pineda. A plasmid en-
coding Tet-inducible Flag-CHK1 was described previously (16) and was
provided by You-Wei Zhang. pEFF-CDT1 was described previously (25)
and was provided by Anindya Dutta. pDEST-N-Myc-CDT2 was provided
by Wade Harper and Malavika Raman. CHK1 3RE and CHK1 A36F (ki-
nase-inactive) mutants, claspin binding mutants (K54A, R129A, and
T153A), a CHK1 phosphorylation site mutant (3SA), CHK1 PIP box mu-
tants (NPIP1, NPIP2, and 2FA), and the CDT2 R246A (RA) mutant
were generated by using the QuikChange II XL site-directed mutagenesis
kit (Agilent Technologies). Lipofectamine 2000 transfection reagent (Life
Technologies) was used for plasmid transfections. For RNA interference
(RNAi) studies, Luciferase GL3 Duplex and SMARTpool small interfering
RNAs (siRNAs) specific for CUL1, CUL4, DDB1, CDT2, or PCNA were
obtained from Thermo Scientific and transfected with DharmaFECT 1
siRNA transfection reagent (Thermo Scientific). The CDT2 SMARTpool
consisted of four siRNAs that were tested individually as well (CDT2-5
[GCGCUUGAAUAGAGGCUUA], CDT2-6 [ACUCCUACGUUCUCU
AUUA], CDT2-7 [GAAUUAUACUGCUUAUCGA], and CDT2-8 [GUC
AAGACCUGGCCUAGUA]).
Coimmunoprecipitation. Cells were lysed in mammalian cell lysis
buffer (MCLB) (50 mM Tris-HCl [pH 8.0], 0.5% NP-40, 5 mM EDTA,
100 mM NaCl, 2 mM dithiothreitol [DTT]) containing protease (Sigma)
and phosphatase (Calbiochem) inhibitor cocktails. Cell lysates were pre-
cleared with protein A-agarose (Thermo Scientific) and incubated with
anti-Flag M2 affinity gel (Sigma). Immunocomplexes were washed with
MCLB, eluted with Flag peptide, and analyzed by Western blotting. Alter-
natively, endogenous CHK1 was immunoprecipitated from precleared
lysates by using protein A-agarose and affinity-purified anti-CHK1 anti-
body.
Protein phosphatase treatment. Protein phosphatase treatment of
cell lysates was performed according to previously reported protocols
(26), with the indicated modifications. Cells were lysed in MCLB lacking
EDTA (50 mM Tris-HCl [pH 8.0], 0.5% NP-40, 100 mM NaCl, 2 mM
DTT) and supplemented with a protease inhibitor cocktail. Cleared ly-
sates were incubated with MnCl2 and Lambda protein phosphatase (New
England BioLabs) at 30°C for 20 min, and reactions were terminated by
boiling in SDS-PAGE loading buffer.
Immunofluorescence. Cells grown on coverslips were fixed with 4%
formaldehyde for 10 min at room temperature and permeabilized with
0.5% Triton X-100 in phosphate-buffered saline (PBS). After blocking
with 5% normal donkey serum in 0.1% Triton X-100 in PBS, cells were
stained with mouse anti-Flag (M2) antibody and rabbit anti-CDT2 anti-
body followed by donkey anti-mouse IgG (fluorescein isothiocyanate
[FITC]) and anti-rabbit IgG (Cy5) secondary antibodies in blocking so-
lution. Coverslips were mounted by using ProLong Gold Antifade reagent
with 4=,6-diamidino-2-phenylindole (DAPI) (Life Technologies). Images
were acquired by using an Olympus BX61 microscope, a Hamamatsu
c10600 camera, a UPlanFl 40 lens, and Olympus MicroSuite software.
In vitro ubiquitination. CHK1 ubiquitination in vitro was performed
as described previously (15), with the following modifications. Flag-
CHK1 was purified from HU-treated 293T cells to promote CHK1 phos-
phorylation. Immunoprecipitated Flag-CHK1 was sequentially washed
with lysis buffer (20 mM Tris-HCl [pH 8.0], 0.5% NP-40, 1 mM EDTA,
150 mM NaCl), LiCl buffer (50 mM Tris-HCl [pH 8.0], 0.5 M LiCl), and
ubiquitination buffer (25 mM Tris-HCl [pH 7.5], 5 mM MgCl2, 2 mM
NaF) and then eluted with Flag peptide in ubiquitination buffer. CRL4
complexes were purified from HU-treated HeLa cells by using protein
A-agarose and an anti-CUL4A antibody (Rockland Immunochemicals).
Immunoprecipitated CRL4 complexes were consecutively washed with
lysis buffer and ubiquitination buffer. Ubiquitination reactions were car-
ried out with Flag-CHK1 (substrate), CRL4 complex, 0.1M E1 (Sigma),
0.4M E2 (Sigma), and 10g bovine ubiquitin (Sigma) in ubiquitination
buffer supplemented with 2 mM ATP and 0.6 mM DTT at 37°C for 75
min, and reactions were terminated by boiling in SDS-PAGE loading
buffer.
Cell fractionation. The fractionation of cellular protein was per-
formed according to previously reported methods, with modifications
(14, 27). Cells were harvested by trypsinization, washed in PBS, and re-
suspended in solution A (10 mM HEPES [pH 7.9], 10 mM KCl, 1.5 mM
MgCl2, 0.34 M sucrose, 10% glycerol, 1 mM DTT) containing 0.1% Tri-
ton X-100 and protease and phosphatase inhibitor cocktails. Supernatants
(cytoplasmic fractions) were collected after centrifugation at 1,300 g for
4 min at 4°C. Nuclear pellets were washed twice with solution A without
Triton X-100 and then resuspended in LS buffer (10 mM Tris-HCl [pH
7.4], 0.2 mM MgCl2) containing 1% Triton X-100 and protease and phos-
phatase inhibitor cocktails. After centrifugation at 1,700 g for 4 min at
4°C, supernatants (soluble nuclear fractions) were collected, and pellets
were washed twice with LS buffer. Chromatin fractions were collected in
increasing salt concentrations (0.3, 0.5, and 2.0 M NaCl in LS buffer),
which extract proteins that are bound to chromatin weakly, moderately,
and strongly, respectively. For coimmunoprecipitations, detergent and
salt concentrations of each fraction were matched, and endogenous
CHK1 was immunoprecipitated by using affinity-purified anti-CHK1 an-
tibody.
Cell cycle analysis. Cells were harvested by trypsinization and fixed in
70% ethanol at 4°C. Cells were washed with 1% bovine serum albumin
(BSA) in PBS and incubated in 1% BSA in PBS containing 30 g/ml
propidium iodide (Sigma) and 250 g/ml RNase A for 1 h at room tem-
perature. Flow cytometry was performed by using a FACSCalibur flow
cytometer (BD Biosciences) and analyzed by using CellQuest software
(BD Biosciences).
Statistical analysis. The quantitation of Western blots was performed
by using ImageJ software (28). Data were analyzed by Student’s t test, and
statistically significant differences are indicated as P values of0.05 (), P
values of0.01 (), and P values of0.005 (). All data are presented
as means standard errors of the means (SEM).
RESULTS
CRL4 is a major regulator of CHK1 stability. Individual contri-
butions to CHK1 destruction made by CRL1 and CRL4 were in-
vestigated by using HeLa cells. The knockdown of CUL4 but not
CUL1 resulted in an increase in CHK1 levels both in normal cy-
cling cells and in cells experiencing replication stress due to hy-
droxyurea (HU) exposure (Fig. 1A and B). Similar results were
obtained when HeLa cells were exposed to UV radiation (Fig. 1C).
These results indicate that the function of CRL1 and CRL4 is not
entirely redundant and that CUL4 assembles the predominant E3
ligase complex required for CHK1 destruction in HeLa cells.
The C terminus of CHK1 contains an autoinhibitory region
(AIR) that is relieved during periods of replication stress due to
phosphorylation on S317 and S345 (29, 30). The resulting confor-
mational change exposes a degron that facilitates the ubiquitin-
mediated proteolysis of CHK1 (16). CHK1 autoinhibition can be
constitutively relieved by mutating three highly conserved argi-
nine (R) residues within its C terminus to glutamate (E). This
mutant (CHK1 3RE) has a very short half-life in cells (16). As
shown in Fig. 1D, the CHK1 3RE mutant was expressed at much
lower levels than the CHK1 WT (wild type), but its association
with CUL1 and CUL4A (lanes 3 and 6) was greater than that of the
CHK1 WT (lanes 2 and 5) (16). A CHK2 mutant encoding a sub-
stitution of alanine for serine at position 379 (SA) was used as a
Huh and Piwnica-Worms
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negative control (26). This suggests that CRL4-mediated ubiquiti-
nation also contributes to the rapid turnover of the CHK1 3RE
mutant.
CDT2 is a novel CHK1 regulator. We identified DDB1 as an
adaptor protein that mediates CHK1 ubiquitination by CRL4
(15). However, attempts to reconstitute direct interactions be-
tween CHK1 and DDB1 in vitro with purified components were
unsuccessful (data not shown). As CRL4 complexes often require
additional substrate receptors called DCAFs to recruit substrates
to CRL4, we hypothesized that the interaction between CHK1 and
CRL4 is mediated by a substrate receptor. CDT2 is a DCAF in-
volved in the S-phase and DNA damage-specific degradation of
key cell cycle regulatory proteins such as CDT1, p21, and SET8
(23, 31–41). CHK1 degradation occurs after its phosphorylation
and activation by ATR. Given that CHK1 is activated in the S and
G2 phases of the cell cycle in normal cycling cells as well as in
response to replication stress, we tested whether CDT2 serves as a
substrate receptor for CHK1.
The turnover of CHK1 was monitored in HeLa cells depleted of
CDT2 in both the absence and presence of replication stress (Fig.
2A and B). The ability of replication stress (HU) to induce CHK1
turnover was significantly impaired in CDT2-depleted cells rela-
tive to control cells (P value of 0.0065). In the absence of replica-
tion stress, the CDT2 knockdown had a more modest effect on
CHK1 turnover (P value of 0.088). CHK1 turnover was also im-
paired in HU-treated HEK293 cells depleted of CDT2 (data not
shown). Furthermore, the stabilization of CHK1 in HU-treated
HeLa cells was observed when CDT2 was depleted with several
distinct siRNAs (Fig. 2C) and when cells were cultured in the
presence of 0.5 to 5.0 mM HU (Fig. 2D). Phosphatase experiments
were performed in advance of SDS-PAGE and Western blotting in
order to dephosphorylate CHK1 prior to determining its relative
levels in control and CDT2-depleted cells. This experiment was
performed to rule out the possibility that the CHK1 antibody used
in our study poorly recognized the phosphorylated forms of
CHK1. As shown in Fig. 2E, phosphatase treatment did not alter
the conclusion that a CDT2 deficiency impairs CHK1 turnover in
HU-treated cells. In addition to HU treatment, the stabilization of
CHK1 was also observed in CDT2-depleted cells exposed to UV
radiation (Fig. 2F, lanes 3 and 4).
In the absence of replication stress, the depletion of CDT2 did
not increase CHK1 levels as much as did the depletion of CUL4
(Fig. 1B and 2B). However, in the presence of replication stress,
CHK1 accumulated to similar levels in CDT2- and CUL4-de-
pleted cells (Fig. 2G). In addition, CHK1 turnover was signifi-
cantly delayed when CDT2-depleted HeLa cells were exposed to
HU (Fig. 3A and B) or UV radiation (Fig. 3C and D). Due to
cycloheximide-induced CDT2 turnover (Fig. 4D), it was difficult
to compare CHK1 levels in control and CDT2-depleted cells in the
presence of cycloheximide. To compare CHK1 destruction in the
absence of cycloheximide, we utilized a Tet-on inducible expres-
sion system (16) (Fig. 3E). CHK1 expression was induced in con-
trol and CDT2-depleted cells by culturing cells in the presence of
doxycycline, and levels of ectopic CHK1 were monitored after the
removal of doxycycline. As shown in Fig. 3E, the turnover of
ectopic CHK1 was observed for control cells (lanes 1 to 3) but not
for CDT2-depleted cells (lanes 4 to 6).
The depletion of CDT2 results in CDT1 accumulation, rerep-
lication, and checkpoint activation (23). CDT1 was overproduced
in HeLa cells to determine if the CHK1 stabilization observed for
CDT2-depleted cells was an indirect effect of the accumulation of
CDT1 (Fig. 3F). If this was the case, we would expect to observe
the stabilization of CHK1 in CDT1-overproducing cells. How-
ever, in three independent experiments, we observed a10% re-
duction in CHK1 levels in CDT1-overproducing cells relative to
control cells in the absence of HU. This is likely due to the gener-
ation of phosphorylated CHK1 (the substrate for ubiquitination)
in CDT1-overproducing cells (Fig. 3F, lane 2). In the presence of
HU, we measured a60% reduction in CHK1 levels in both con-
trol and CDT1-overproducing cells. Thus, the effects of the deple-
tion of CDT2 on CHK1 turnover are not explained by the accu-
mulation of CDT1 in CDT2-depleted cells.
CDT2 targets CHK1 to CRL4CDT2. Next, experiments were
performed to determine if interactions between CDT2 and CHK1
could be detected. As shown in Fig. 4A, both the CHK1 WT and
the CHK1 3RE mutant coprecipitated with CDT2, and these in-
teractions were enhanced when cells were cultured in the presence
of HU to induce replication stress (lanes 2 and 4). Despite lower
levels of the CHK1 3RE mutant than the CHK1 WT, greater inter-
actions were observed between CDT2 and the CHK1 3RE mutant
(Fig. 4A, lanes 3 and 4), consistent with the enhanced interactions
between CUL4A and the CHK1 3RE mutant (Fig. 1D). CHK1 and
CDT2 exhibited predominant nuclear localization both in the ab-
sence and in the presence of replication stress, demonstrating that
they are present in the same cellular compartment (Fig. 4B). Next,
FIG 1 CRL4 is a major regulator of CHK1 stability. (A and B) Contributions
made by CRL1 and CRL4 to CHK1 stability. HeLa cells transfected with con-
trol siRNA (GL3) or siRNAs specific for either CUL1 or CUL4 were cultured
for 48 h and then incubated in the absence or presence of 5 mM HU for 6 h. Cell
lysates were analyzed by Western blotting. A representative experiment is
shown in panel A, and the quantitation of data from 3 independent experi-
ments is shown in panel B. (C) Effects of UV on CHK1 stability. HeLa cells
transfected with control siRNA or siRNAs specific for CUL1 or CUL4 were
mock irradiated or exposed to 50 J/m2 UV at 48 h posttransfection. Cells were
harvested 6 h later and analyzed by Western blotting. Levels of CHK1 in knock-
down cells are shown relative to levels in control cells (lane 1). (D) Interactions
between CUL4A and CHK1. The Flag-tagged CHK1 WT or the CHK1 3RE or
CHK2 SA mutant was coproduced with V5-tagged CUL1 or CUL4A in HeLa
cells. Cell lysates were resolved directly by SDS-PAGE or were immunopre-
cipitated with anti-Flag M2 affinity gel prior to SDS-PAGE. Whole-cell lysates
(WCL) and immunoprecipitates (IP: Flag) were then analyzed by Western
blotting. CUL1 and CUL4A were detected by using an anti-V5 antibody.
CRL4CDT2 Targets CHK1 for Destruction
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we examined the ability of CUL4A and DDB1 to coprecipitate
with CHK1 in the presence of a CDT2 R246A (RA) mutant, a
mutant of CDT2 that is defective for DDB1 binding (23). As
shown in Fig. 4C, the ability of DDB1 and CUL4A to coprecipitate
with CHK1 was reduced in the presence of the CDT2 RA mutant
(lane 3) relative to the CDT2 WT (lane 2). Levels of DDB1 and
CUL4A present in CDT2 RA precipitates (Fig. 4C, lane 3) were
similar to those present in precipitates from control cells (lane 1)
and therefore are likely due to nonspecific binding. These results
provide additional evidence that CDT2 serves as a substrate recep-
tor for CHK1.
Interestingly, endogenous CDT2 accumulated under condi-
tions of replication stress (Fig. 2A and D, 3A and E, and 4D).
This was not observed when cells were treated with cyclohexi-
mide to prevent new protein synthesis (Fig. 4D), and ectopi-
cally expressed CDT2 did not accumulate under similar condi-
tions (Fig. 4A). Thus, increases in endogenous CDT2 levels
were due to changes at the transcriptional and/or translational
level rather than at the level of protein stability. CDT2 accu-
mulation in response to replication stress correlated with en-
hanced CHK1 turnover (Fig. 3A).
Next, ubiquitination assays were performed to determine if the
depletion of CDT2 impaired the ability of the CRL4 complex to
ubiquitinate CHK1 in vitro. CHK1 was isolated from HU-treated
cells to facilitate CHK1 phosphorylation on S317 and S345 be-
cause CHK1 phosphorylation on these residues promotes its
binding to CRL4 (15–17). The CRL4 complex was isolated from
cells transfected with control siRNA as well as from cells knocked
down for CDT2 or DDB1 (Fig. 4E). As shown in Fig. 4F, the CRL4
complex isolated from cells deficient in either CDT2 (lane 5) or
DDB1 (lane 6) was less effective at ubiquitinating CHK1 than the
CRL4 complex isolated from control cells (lane 4). These results
indicate that CDT2 functions as a substrate receptor that targets
CHK1 to CRL4CDT2.
FIG 2 CDT2 is a novel CHK1 regulator. (A and B) CDT2 is required for CHK1 turnover. HeLa cells transfected with control siRNA (GL3) or pooled siRNAs
specific for CDT2 were cultured for 48 h and then incubated in the absence or presence of 5 mM HU for 6 h. Cell lysates were analyzed by Western blotting. A
representative experiment is shown in panel A, and the quantitation of data from 3 independent experiments is shown in panel B (N.S., not statistically significant
by Student’s t test). (C) Regulation of CHK1 by CDT2. HeLa cells transfected with control siRNA or individual siRNAs specific for CDT2 were cultured for 48
h and then incubated in the presence of 5 mM HU for 6 h. Cell lysates were analyzed by Western blotting. (D) Effects of HU on CHK1 turnover. HeLa cells
transfected with control siRNA or siRNA specific for CDT2 were cultured for 48 h and then incubated in the presence of the indicated doses of HU for 6 h. Cell
lysates were analyzed by Western blotting. (E) CHK1 levels after dephosphorylation in vitro. HeLa cells transfected with control siRNA or siRNAs specific for
CDT2 were cultured for 48 h and then incubated in medium containing 5 mM HU for 6 h. Cell lysates were incubated in the absence or presence of Lambda
protein phosphatase (PPase), followed by Western blotting. Levels of CHK1 in cells knocked down for CDT2 are shown relative to levels in control cells (lanes
1 and 3). (F) Effects of UV on CHK1 turnover. HeLa cells transfected with control siRNA or siRNA specific for CDT2 were mock irradiated or exposed to 50 J/m2
UV at 48 h posttransfection. Cells were harvested 6 h later and analyzed by Western blotting. Levels of CHK1 in knockdown cells are shown relative to levels in
control cells (lane 1). (G) Regulation of CHK1 stability by CRL1, CRL4, and CDT2. HeLa cells transfected with control siRNA or siRNAs specific for CUL1, CUL4,
or CDT2 were cultured for 48 h and then incubated in the presence of 5 mM HU for 6 h. Cell lysates were analyzed by Western blotting. Levels of CHK1 in
knockdown cells are shown relative to levels in control cells (lane 1).
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Claspin binding is required for CHK1 ubiquitination. Claspin
serves as a mediator that recruits CHK1 to sites of DNA damage,
where it is phosphorylated on S317 and S345 by ATR. Phosphoryla-
tion relieves CHK1 autoinhibition, leading to the activation of its
kinase activity and autophosphorylation on S296 (10, 42). We
next asked if the kinase activity of CHK1 or its recruitment to
DNA lesions by claspin was required for CHK1 to bind to
CRL4CDT2. Several CHK1 mutants were generated for this pur-
pose, including a kinase-inactive CHK1 mutant (A36F) and three
claspin binding mutants (K54A, R129A, and T153A) (Fig. 5A).
WT or mutant forms of CHK1 were coproduced with CDT2 in
HeLa cells and examined for their abilities to coprecipitate with
one another. As expected, the kinase-inactive mutant (CHK1
A36F) was not phosphorylated on S296, the CHK1 autophos-
phorylation site (Fig. 5B, lane 3). The CHK1 A36F mutant bound
claspin (Fig. 5B, lane 3), its levels of phosphorylation on S345 and
binding to CDT2 were higher than those of the CHK1 WT (Fig.
5B, lanes 2 and 3), and it had a shorter half-life than the CHK1 WT
(Fig. 5C and D). Thus, CHK1 kinase activity was not required for
CHK1 to bind to CRL4CDT2.
As expected, the claspin binding mutants of CHK1 did not inter-
act with claspin (Fig. 5B, lanes 4 to 6). The inability to bind claspin has
been shown to reduce the recruitment of CHK1 to ATR (43), and as
a result, the claspin binding mutants exhibited less phosphorylation
on S345 and S296 than the CHK1 WT (Fig. 5B, lanes 2 and 4 to 6). In
addition, the claspin binding mutants exhibited reduced CDT2 bind-
ing (Fig. 5B, lanes 2 and 4 to 6) and longer half-lives than the CHK1
WT (Fig. 5C and D). Thus, the recruitment of CHK1 to sites of DNA
damage by claspin is an important step in mediating interactions
between CHK1 and CRL4CDT2, and this is likely because CHK1 in-
teractions with CRL4CDT2 are facilitated by the ATR-mediated phos-
phorylation of CHK1. We also included experiments with a CHK1
phosphorylation site mutant (3SA) encoding a substitution of ala-
nine for serine at each of the ATR phosphorylation sites (S317, S345,
and S366). As shown in Fig. 5E, the CHK1 3SA mutant was more
stable than the CHK1 WT, demonstrating the importance of ATR-
mediated phosphorylation in regulating CHK1 turnover.
CRL4CDT2 targets CHK1 for PCNA-independent degrada-
tion. PCNA plays a critical role in recruiting CDT2 substrates to
CRL4CDT2 for ubiquitin-mediated proteolysis. In fact, with the
FIG 3 CDT2 regulates CHK1 turnover in response to replication stress. (A and B) HU-induced CHK1 turnover in CDT2-depleted cells. HeLa cells transfected
with control siRNA (GL3) or siRNA specific for CDT2 were cultured for 48 h and then incubated in medium containing 5 mM HU in the absence or presence
of 10 M MG132. At the indicated times post-HU treatment, cells were harvested and analyzed by Western blotting. A representative experiment is shown in
panel A, and the quantitation of data from 5 independent experiments is shown in panel B. (C and D) UV-induced CHK1 turnover in CDT2-depleted cells. HeLa
cells transfected with control siRNA or siRNA specific for CDT2 were exposed to 50 J/m2 UV at 48 h posttransfection. Cells were then cultured in the absence or
presence of 10 M MG132. At the indicated times post-UV exposure, cells were harvested and analyzed by Western blotting. A representative experiment is
shown in panel C, and the quantitation of data from 4 independent experiments is shown in panel D. (E) Prolonged half-life of CHK1 in CDT2-depleted cells.
HeLa Tet-on cells were transfected with a plasmid encoding Tet-inducible Flag-CHK1 followed by either control siRNA or siRNA specific for CDT2. Cells were
cultured in the presence of 0.2 g/ml doxycycline for 14 h to induce Flag-CHK1 expression. Cells were washed, cultured for 4 h in fresh medium, and then
cultured in medium containing 5 mM HU. At the indicated times post-HU treatment, cells were harvested and analyzed by Western blotting. Levels of
Flag-CHK1 are shown relative to levels at the 0-h time points (lanes 1 and 4). (F) Effects of CDT1 overexpression on CHK1 stability. HeLa cells expressing
Flag-tagged CDT1 for 24 h were incubated in the absence or presence of 5 mM HU for 6 h. Cell lysates were analyzed by Western blotting. The arrowhead indicates
endogenous CDT1.
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exception of SPD1, EPE1, and GCN5, all known targets of CDT2
contain a highly conserved PIP degron that mediates interactions
with chromatin-bound PCNA to recruit these substrates to
CRL4CDT2 (24, 31, 33, 44–46). In most cases, PCNA knockdown
results in substrate accumulation (23, 31–34, 37, 47, 48). CHK1
was reported previously to interact with PCNA through a nonca-
nonical PIP box (49), and therefore, we tested whether the knock-
down of PCNA impaired CHK1 proteolysis in HeLa cells. CHK1
levels did not significantly change in cells knocked down for
PCNA (Fig. 6A to C), and the rate of CHK1 turnover did not
change when PCNA-deficient cells were subjected to replication
stress (Fig. 6D and E). This is in contrast to the knockdown of
CUL4 (Fig. 1), CDT2 (Fig. 2), or DDB1 (15), where CHK1 accu-
mulation was readily observed. As a positive control for the PCNA
knockdown, we monitored the turnover of CDT1, a canonical
CDT2 substrate (24). The ubiquitin-mediated proteolysis of
CDT1 by CRL4CDT2 is dependent on PCNA binding, whereas its
destruction by CRL1SKP2 is PCNA independent (24, 50). Because
FIG 4 CDT2 serves as the substrate receptor that targets CHK1 to CRL4CDT2. (A) Interactions between CHK1 and CDT2. Flag-tagged WT or a mutant form
(3RE) of CHK1 was coproduced with Myc-tagged CDT2 in HeLa cells for 24 h. Cells were then cultured in medium containing 5 mM HU and 10 M MG132
for 4 h. Cell lysates were resolved directly by SDS-PAGE or were immunoprecipitated with anti-Flag M2 affinity gel prior to SDS-PAGE. Whole-cell lysates (WCL)
and immunoprecipitates (IP: Flag) were then analyzed by Western blotting. (B) Subcellular localization of CHK1 and CDT2. Flag-tagged CHK1 was produced
in HeLa cells for 48 h. Cells were then cultured in the absence or presence of 5 mM HU or 10 M MG132 for 4 h. The localization of endogenous CDT2 and
ectopic CHK1 was determined by immunofluorescence staining. (C) Interactions between CHK1 and CRL4CDT2. Flag-tagged CHK1 was coproduced with the
Myc-tagged CDT2 WT or CDT2 RA mutant in HeLa cells for 24 h. Cells were exposed to 50 J/m2 UV and cultured in the presence of 10M MG132 for 2 h. Cell
lysates were resolved directly by SDS-PAGE or were immunoprecipitated with anti-Flag M2 affinity gel prior to SDS-PAGE. Whole-cell lysates and immuno-
precipitates were then analyzed by Western blotting. (D) Regulation of CDT2 levels in response to replication stress. HeLa cells were cultured in medium
containing 50 g/ml cycloheximide (CHX), 5 mM HU, or both. At the indicated times post-HU/CHX treatment, cells were harvested and analyzed by Western
blotting. (E and F) CHK1 ubiquitination in vitro. HeLa cells transfected with control siRNA (GL3) or siRNAs specific for either CDT2 or DDB1 were cultured for
48 h and then incubated in the presence of 10 mM HU for 1 h. Cell lysates were prepared, and a portion was resolved directly by SDS-PAGE followed by Western
blotting (E). The remaining lysates were immunoprecipitated with anti-CUL4A antibody. Immunoprecipitated CRL4 complexes were then incubated with
purified E1, E2, ubiquitin, and Flag-CHK1 that had been purified from HU-treated cells (F). Long (L) and short (S) exposures are indicated.
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the turnover of CDT1 in HeLa cells is regulated by both CRL1 and
CRL4, we depleted CUL1 so that the effects of the PCNA depletion
on the ubiquitin-mediated proteolysis of CDT1 by CRL4CDT2
could be monitored under conditions that minimized compensa-
tion by CRL1. The depletion of CUL1 alone or the codepletion of
CUL1 and PCNA resulted in CDT1 but not CHK1 stabilization
both in the absence and in the presence of replication stress (Fig.
6F and G). A slower-migrating form of CDT1 was observed upon
the codepletion of both CUL1 and PCNA (Fig. 6F, lanes 3 and 6).
The modification causing this change in electrophoretic mobility
is not known but could be due to the stabilization of a phosphor-
ylated or ubiquitinated form of CDT1. Another canonical CDT2
FIG 5 Claspin binding is important for CHK1 regulation by CRL4CDT2. (A) Schematic representation of CHK1 indicating the domain structure as well as
kinase-inactive (A36F), claspin binding (K54A, R129A, and T153A), and SQ/TQ phosphorylation site (3SA) mutants. (B) Role of kinase activity and claspin
binding in mediating interactions between CHK1 and CDT2. Flag-tagged WT or mutant forms of CHK1 were coproduced with Myc-tagged CDT2 for 24 h and
then cultured in medium containing 5 mM HU and 10 M MG132 for 4 h. Cell lysates were resolved directly by SDS-PAGE or were immunoprecipitated with
anti-Flag M2 affinity gel prior to SDS-PAGE. Whole-cell lysates (WCL) and immunoprecipitates (IP: Flag) were analyzed by Western blotting. (C and D)
Contributions made by kinase activity and claspin binding to CHK1 turnover. HeLa cells expressing the CHK1 WT or the indicated CHK1 mutants were cultured
in medium containing 10 g/ml CHX and 5 mM HU in the absence or presence of 10 M MG132. At the indicated times post-HU/CHX treatment, cells were
harvested and analyzed by Western blotting. A representative experiment is shown in panel C, and the quantitation of data from 4 independent experiments is
shown in panel D. (E) Role of ATR-mediated phosphorylation in CHK1 turnover. HeLa cells expressing the CHK1 WT or the CHK1 3SA mutant were cultured
in medium containing 10 g/ml CHX and 5 mM HU in the absence or presence of 10 M MG132. At the indicated times post-HU/CHX treatment, cells were
harvested and analyzed by Western blotting. Levels of Flag-CHK1 are shown relative to levels at the 0-h time points.
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substrate, SET8, was also stabilized by the depletion of PCNA (Fig.
6F, lanes 3 and 6) (31, 33, 35, 38, 41). Taken together, these results
indicate that the ability of CRL4CDT2 to target CHK1 for ubiqui-
tin-mediated proteolysis is independent of PCNA binding.
CHK1 PIP boxes are dispensable for CRL4CDT2-mediated
degradation. As mentioned above, CHK1 contains a noncanoni-
cal PIP box (residues 371 to 385) within its C terminus (CPIP)
(Fig. 7A), and phenylalanine residues at position 380 (F380) and
381 (F381) were shown previously to be necessary for PCNA bind-
ing (49). We generated the CHK1 2FA mutant (containing alanine
in place of F380 and F381) and monitored its ability to bind to
CDT2. If PCNA is required to facilitate the binding of CHK1 to
CDT2, we predicted that the 2FA mutant would bind less CDT2
than would the CHK1 WT and that its half-life would be longer.
As shown in Fig. 7B, interactions between the CHK1 2FA mutant
and CDT2 (lane 3) were actually greater than those observed be-
tween the CHK1 WT and CDT2 (lane 2), and the half-life of the
CHK1 2FA mutant was shorter than that of the CHK1 WT (Fig.
7C and D). Thus, the C-terminal PIP box of CHK1 was not re-
quired for the targeting of CHK1 to CRL4CDT2, and the disruption
of key residues within the putative PIP box actually promoted
interactions between CHK1 and CDT2. This is likely due to a relief
of the C-terminal autoinhibitory region of CHK1 and the expo-
sure of its degron. In support of this, the kinase activities of the
CHK1 2FA and 3RE mutants were shown to be greater than that of
the CHK1 WT (16, 49), and both mutants exhibited enhanced
autophosphorylation on S296 relative to the CHK1 WT (Fig. 7B,
lanes 2 to 4), which is indicative of relief from autoinhibition.
CHK1 also contains a potential PIP degron (residues 64 to 75)
within its N terminus (NPIP) (Fig. 7A). We generated mutants of
CHK1, denoted NPIP1 (encoding an alanine substitution for
both F70 and Y71) andNPIP2 (encoding an alanine substitution
for both R74 and R75), in combination with the 3RE mutations to
test the contribution made by the putative N-terminal PIP degron
to CDT2 binding and CHK1 proteolysis. The mutation of residues
predicted to disrupt the N-terminal PIP box and PCNA binding
(NPIP1) enhanced rather than impaired interactions between
CHK1 and CDT2 (Fig. 7E, lane 3). The CHK1 NPIP1 mutant
was phosphorylated on S345 by ATR, indicating relief from auto-
inhibition. However, autophosphorylation on S296 was not ob-
FIG 6 CRL4CDT2 targets CHK1 for PCNA-independent degradation. (A and B) Role of PCNA binding in regulating CHK1 stability. HeLa cells transfected with
control siRNA (GL3) or siRNA specific for PCNA were cultured for 48 h and then incubated in the absence or presence of 5 mM HU for 6 h. Cell lysates were
analyzed by Western blotting. A representative experiment is shown in panel A, and the quantitation of data from 3 independent experiments is shown in panel
B. (C) PCNA binding is not required for CHK1 turnover in UV-treated cells. HeLa cells transfected with control siRNA or siRNA specific for PCNA were mock
irradiated or exposed to 50 J/m2 UV at 48 h posttransfection. Cells were harvested 6 h later and analyzed by Western blotting. Levels of CHK1 in knockdown cells
are shown relative to levels in control cells (lane 1). (D and E) HU-induced CHK1 turnover in PCNA-depleted cells. HeLa cells transfected with control siRNA
or siRNA specific for PCNA were cultured for 48 h and then incubated in medium containing 5 mM HU in the absence or presence of 10 M MG132. At the
indicated times post-HU treatment, cells were harvested and analyzed by Western blotting. A representative experiment is shown in panel D, and the quantitation
of data from 4 independent experiments is shown in panel E. (F and G) PCNA is required for CDT1 and SET8 but not CHK1 turnover. HeLa cells transfected with
control siRNA, siRNA specific for CUL1, or siRNAs specific for CUL1 and PCNA were cultured for 48 h and then incubated in the absence or presence of 5 mM
HU for 6 h. Cell lysates were analyzed by Western blotting. A representative experiment is shown in panel F, and the quantitation of data from 3 independent
experiments is shown in panel G. In panels B, E, and G, differences were not significant between control cells and PCNA, CUL1, or CUL1/PCNA knockdown cells
within either treatment condition (Student’s t test).
Huh and Piwnica-Worms
220 mcb.asm.org Molecular and Cellular Biology
 o
n








served, indicating that this mutant lacked kinase activity. We also
tested the importance of the N-terminal PIP degron by mutating
two basic residues within this region (NPIP2) in the CHK1 3RE
mutant. We predicted that these mutations would impair CDT2
binding and extend the half-life of the CHK1 3RE mutant contain-
ing an intact N-terminal PIP degron. This prediction was not met,
as CDT2 binding was not impaired when mutations within the
N-terminal PIP degron were introduced (Fig. 7E, lane 5), and the
FIG 7 CHK1 PIP boxes are dispensable for CRL4CDT2-mediated destruction. (A) Schematic representation of CHK1 indicating the domain organization. The putative
N-terminal PIP degron (NPIP box), C-terminal PIP box (CPIP box), and PIP box mutants (NPIP1,NPIP2, and 2FA) are shown. Conserved residues in the canonical
PIP box and PIP degron are shown in black and dark gray, respectively. Additional residues that are highly conserved in CHK1 PIP boxes are shown in dark gray. (B) Role
of the CPIP box in mediating CDT2 binding. The indicated Flag-tagged proteins were coproduced with Myc-tagged CDT2 in HeLa cells for 24 h and then cultured in
medium containing 5 mM HU and 10 M MG132 for 4 h. Cell lysates were resolved directly by SDS-PAGE or were incubated with anti-Flag M2 affinity gel prior to
SDS-PAGE. Whole-cell lysates (WCL) and immunoprecipitates (IP: Flag) were analyzed by Western blotting. Levels of pS296 were normalized to levels of precipitated
Flag-CHK1 and are shown relative to those of the CHK1 WT. (C and D) Role of the CPIP box in regulating CHK1 stability. HeLa cells expressing the CHK1 WT or the
CHK1 2FA mutant were cultured in medium containing 10 g/ml CHX and 5 mM HU in the absence or presence of 10 M MG132. At the indicated times
post-HU/CHX treatment, cells were harvested and analyzed by Western blotting. A representative experiment is shown in panel C, and the quantitation of data from 3
independent experiments is shown in panel D. Long (L) and short (S) exposures are indicated. (E) Role of the CHK1 NPIP box in mediating CDT2 binding. The indicated
Flag-tagged proteins were coproduced with Myc-tagged CDT2 in HeLa cells for 24 h and then cultured in medium containing 5 mM HU and 10M MG132 for 4 h. Cell
lysates were resolved directly by SDS-PAGE or were incubated with anti-Flag M2 affinity gel prior to SDS-PAGE. Whole-cell lysates and immunoprecipitates were
analyzed by Western blotting. Levels of pS296 were normalized to levels of precipitated Flag-CHK1 and are shown relative to those of the CHK1 WT. (F and G) Role of
the NPIP box in regulating CHK1 stability. HeLa cells expressing the CHK1 3RE or 3RENPIP2 mutant were cultured in medium containing 10g/ml CHX and 5 mM
HU. Cells were harvested and analyzed by Western blotting at the indicated times posttreatment. A representative experiment is shown in panel F, and the quantitation
of data from 3 independent experiments is shown in panel G.
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half-life of the CHK1 3RE NPIP2 mutant was indistinguishable
from that of the CHK1 3RE mutant (Fig. 7F and G).
CRL4CDT2 targets CHK1 for ubiquitination in the nucleo-
plasm. Most CDT2 substrates are recruited to CRL4CDT2 by inter-
actions with chromatin-bound PCNA and removed from chro-
matin by p97 AAA-ATPase (24, 51). Although the recruitment
of CHK1 to sites of DNA damage is a critical step in the targeting
of CHK1 for CRL4-mediated destruction, CHK1 did not require
PCNA for its association with CDT2. Therefore, we asked where
interactions between CHK1 and CRL4CDT2 took place. Cytoplas-
mic, soluble nuclear, and three different chromatin fractions were
isolated from mock- or UV-irradiated HeLa cells. Different chro-
matin fractions were obtained by sequentially washing chromatin
with buffers containing 0.3 M NaCl (fraction 1), 0.5 M NaCl (frac-
tion 2), and 2.0 M NaCl (fraction 3). Each fraction was analyzed
for endogenous CHK1 as well as for components of CRL4CDT2 and
CRL1FBX6. ORC2 (origin recognition complex subunit 2) was
used as a control for chromatin-bound proteins.
As shown in Fig. 8A, ORC2 was found in chromatin fractions 1
and 2. CHK1 was present in cytoplasmic, nuclear, and chromatin
fractions, and its phosphorylated form was enriched in cytoplas-
mic and nuclear fractions, as previously reported (14). DDB1 was
distributed in cytoplasmic, nuclear, and chromatin fractions, as
previously reported (52). Neddylated and nonneddylated forms
of CUL4A were present in all three fractions. Interestingly, in the
chromatin fractions, the neddylated (active) form of CUL4A par-
titioned predominantly in fractions 2 and 3 (Fig. 8A, lanes 13 to
20), indicating that it was tightly bound to chromatin. CDT2, the
substrate receptor for CRL4, was found predominantly in the nu-
clear fraction and chromatin fractions 1 and 2 (Fig. 8A, lanes 5 to
16), whereas FBX6, the substrate receptor for CRL1, was found
predominantly in the cytoplasmic fraction (lanes 1 to 4), as pre-
viously reported (16). Levels of CDT2 in chromatin fractions in-
creased after UV treatment, demonstrating that while a fraction of
CDT2 was redistributed from the nuclear pool to the chromatin-
bound pool, a major fraction of CDT2 remained in the nucleo-
plasm. In contrast, SKP1 and FBX6 were enriched in cytoplasmic
fractions. Thus, CRL4CDT2 components were enriched in the nu-
cleoplasm, while CRL1FBX6 components were enriched in the cy-
toplasm. These results indicate that these E3 ubiquitin ligases
function in distinct cellular compartments.
To examine where interactions between CHK1 and CRL4CDT2
take place, endogenous CHK1 was immunoprecipitated from cy-
toplasmic fractions, soluble nuclear fractions, and chromatin frac-
tions 1 and 2. As shown in Fig. 8B, CHK1 and CDT2 complexes
were enriched in nuclear fractions (lane 8), which are also where
the phosphorylated form of CHK1 resided (Fig. 8A, lanes 6 to 8).
These results indicate that CHK1 ubiquitination by CRL4CDT2
occurs mainly in the nucleoplasm, in contrast to interactions be-
tween CHK1 and the CUL1 substrate receptor FBX6, which occur
in the cytoplasm (16). Thus, CRL1FBX6 and CRL4CDT2 regulate
CHK1 stability in distinct cellular compartments (Fig. 8C).
FIG8 CRL4CDT2 interacts with CHK1 in the nucleoplasm. (A) Spatial regulation of CHK1 ubiquitination by CRL1 and CRL4. HeLa cells were exposed to 20 J/m2
UV and then harvested at the indicated time points post-UV exposure. Subcellular fractionation was performed, and individual fractions were analyzed by
Western blotting. The arrowheads indicate the neddylated form of cullins. (B) Subcellular location of CHK1 interactions with CDT2. HeLa cells were exposed to
50 J/m2 UV. Cytoplasmic (C), soluble nuclear (N), and chromatin (CH) fractions were isolated 2 h later and either resolved directly by SDS-PAGE (input) or
incubated with protein A-agarose either alone (IP: Control) or with affinity-purified anti-CHK1 antibody (IP: CHK1) prior to SDS-PAGE. (C) The checkpoint
activation/termination cycle. In response to replication stress, CHK1 is recruited to sites of DNA damage in a claspin-dependent manner, where it is phosphor-
ylated by ATR. Phosphorylated CHK1 is then released from the chromatin to phosphorylate downstream effectors. Two E3 ubiquitin ligases target CHK1 for
destruction. CRL4CDT2 ubiquitinates CHK1 in the nucleoplasm, whereas CRL1FBX6 ubiquitinates CHK1 in the cytoplasm. This terminates checkpoint signaling
through the ATR/CHK1 pathway.
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CHK1 is required forG2 arrest inCDT2-depleted cells.CDT2
depletion results in rereplication and G2 cell cycle arrest in cul-
tured cells (23, 36, 40). The stabilization of CDT1 by CDT2 deple-
tion contributes to the ability of cells to undergo rereplication
(23). We investigated the role of CHK1 in regulating G2 cell cycle
arrest in CDT2-depleted cells. Since the active form of CHK1
strongly associates with CRL4CDT2, replication stress-induced
CHK1 activation is accompanied by a decrease in the total CHK1
levels (Fig. 1B, 2B, and 6B). However, as shown in Fig. 9A, the S296
phosphorylated (active) form of CHK1 accumulated in CDT2-
depleted cells without a decrease in total CHK1 levels (Fig. 9A,
lane 3, and B), and this correlated with a reduction in the number
of G1- and S-phase cells coincident with an increase in the per-
centage of G2/M-phase cells (Fig. 9C and D). When CDT2-depe-
leted cells were treated with AZD7762 (AZD), a selective CHK1
inhibitor (53), cells bypassed the G2 arrest and moved into the G1
phase (Fig. 9C and D). The loss of S296 phosphorylation con-
firmed the inhibition of CHK1 by AZD7762 (Fig. 9A, lanes 2 and
4). These results indicate that CHK1 kinase activity is required for
maintaining G2 cell cycle arrest in CDT2-depleted cells.
DISCUSSION
In this study, we identified CDT2 as a novel CHK1 regulator.
CDT2 functions as a substrate receptor that targets CHK1 to
CRL4CDT2 for ubiquitin-mediated proteolysis. CHK1 turnover
was observed in cells exposed to replication stress, and CDT2 de-
pletion abrogated replication stress-induced CHK1 turnover in
HeLa cells. This indicates that CDT2 is the predominant substrate
receptor for regulating replication stress-induced CHK1 proteol-
ysis in these cells. The predominant role played by CRL4CDT2, as
opposed to CRL1FBX6, in regulating CHK1 destruction in HeLa
cells is likely due to the low levels of FBX6 in these cells (16).
In the absence of replication stress, the CUL4 depletion (Fig.
1A and B) had a more robust effect on CHK1 levels than did the
CDT2 depletion (Fig. 2A and B). In the absence of HU, there was
a 2-fold increase in CHK1 levels in CUL4A/B-depleted cells rela-
tive to those in control cells, and there was still a 50% reduction in
CUL4A/B-depleted cells after HU treatment. This could be inter-
preted to mean that CUL4 is not responsible for CHK1 destruc-
tion in the presence of replication stress. However, interactions
between CUL4A and CHK1 were well characterized in two previ-
ous studies (15, 17). Zhang et al. previously identified CUL4A (in
addition to CUL1) as an E3 ligase that targets CHK1 for ubiquitin-
mediated proteolysis (17). They also presented evidence that
CUL4B does not regulate CHK1, but this may vary depending on
the cell line studied. We subsequently identified DDB1 in a pro-
teomic screen looking for CHK1-interacting proteins and demon-
strated that CUL4A, together with DDB1, regulates CHK1 turn-
over (15). Here we demonstrated that in the presence of HU, cells
knocked down for either CDT2 or CUL4 accumulate 2-fold more
CHK1 than do control cells (Fig. 1A and B and 2A and B). In
addition, CUL4A coprecipitates with CHK1 (Fig. 1D), a CUL4
deficiency extends the half-life of CHK1 (15), and CUL4A immu-
noprecipitates ubiquitinate CHK1 in vitro (Fig. 4F). Taken to-
gether, these data provide strong evidence that CRL4CDT2 targets
CHK1 for ubiquitination under conditions of replication stress.
What, then, accounts for the relatively higher level of accumula-
tion of CHK1 in CUL4-depleted cells (Fig. 1A and B) than in
CDT2-depleted cells (Fig. 2A and B) in the absence of replication
stress and the 50% reduction in CHK1 levels in HU-treated
CUL4-depleted cells? One explanation for this might be that the
CUL4 depletion indirectly stimulates CHK1 transcription/trans-
lation in the absence but not in the presence of HU treatment. This
would account for the higher level of accumulation of CHK1 in
CUL4-depleted cells than in CDT2-depleted cells in the absence of
replication stress. In addition, if this hypothesis is correct, the
reduction in CHK1 levels observed for HU-treated CUL4-de-
pleted cells would be due to reduced transcription/translation as
opposed to ubiquitin-mediated proteolysis.
Most known substrates of CDT2 contain a specialized PIP box,
and interactions with chromatin-bound PCNA mediate their re-
cruitment to CRL4CDT2 (24). A canonical PIP degron consists of a
PCNA interaction protein motif (PIP box), a TD motif within the
PIP box, and a basic amino acid (K/R) in the4 position (B4)
relative to the PIP box. Havens et al. reported previously that
CRL4CDT2 interacts not only with the substrate via B4 but also
with an acidic residue on PCNA (D122) (24, 50). In the absence of
a basic residue in the4 position, basic residues upstream of the
PIP degron can contribute to the CRL4CDT2-mediated destruction
of the substrate. In addition, a TD motif with the PIP box contrib-
utes to the high-affinity binding of the substrate and PCNA. It was
proposed that CRL4CDT2 is recruited to the PIP degron-PCNA
complex rather than to either protein independently.
The C-terminal PIP box of CHK1 encodes aspartic acid (D385)
FIG 9 CHK1 maintains G2 arrest in CDT2-depleted cells. (A and B) Stabili-
zation of the active form of CHK1 in CDT2-depleted cells. HeLa cells trans-
fected with control siRNA (GL3) or siRNA specific for CDT2 were cultured for
48 h and then incubated in medium containing dimethyl sulfoxide (DMSO) or
30 nM AZD7762 (AZD) for 2 h. Cells were harvested and analyzed by Western
blotting. A representative experiment is shown in panel A, and the quantita-
tion of data from 3 independent experiments is shown in panel B. (C and D) G2
checkpoint regulation by CHK1 and CDT2. HeLa cells transfected with con-
trol siRNA or siRNA specific for CDT2 were cultured for 48 h and then incu-
bated in medium containing dimethyl sulfoxide or 30 nM AZD7762 for 4 h.
Cells were analyzed by flow cytometry. A representative experiment is shown
in panel C, and the quantitation of data from 3 independent experiments is
shown in panel D.
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in the B4 position and does not contain basic residues upstream
of the PIP box. Furthermore, the CPIP box lacks a TD motif. The
putative N-terminal PIP box of CHK1 contains arginines (R74
and R75) in the B3 and B4 positions as well as basic residues
upstream of the PIP box but lacks a TD motif. We found that the
depletion of PCNA did not increase CHK1 stability and that
CHK1 recruitment to CRL4CDT2 did not require either of its PIP
boxes. Interactions between CHK1 and PCNA were shown previ-
ously to decrease during periods of replication stress (49), yet we
observed enhanced interactions between CHK1 and CDT2 during
periods of replication stress. This provides further evidence that
PCNA binding does not mediate interactions between CHK1 and
CRL4CDT2. In fact, enhanced interactions between CHK1 and
CDT2 were observed when conserved residues within the PIP
boxes of CHK1 were mutated. Thus, CHK1 joins a noncanonical
class of CDT2 substrates, including GCN5, that do not require
PCNA binding in order to be targeted to CRL4CDT2 (44–46).
Mutations present in the CHK1 2FA and CHK1 3RE mutants
neighbor the autoinhibitory region (AIR) of CHK1. Previous
studies reported that structural changes within this region relieve
CHK1 autoinhibition and that this in turn activates the kinase
activity of CHK1 while at the same time exposing its degron (16).
Indeed, the CHK1 2FA and CHK1 3RE mutants exhibited elevated
kinase activities (16, 49), enhanced autophosphorylation on S296,
and enhanced turnover relative to the CHK1 WT. However, the
enhanced turnover did not require CHK1 kinase activity or phos-
phorylation on S296, as the kinase-inactive mutant of CHK1 also
exhibited enhanced CDT2 binding and enhanced turnover com-
pared with the CHK1 WT. This is likely because the kinase-inac-
tive mutant is highly phosphorylated on S345, which is sufficient
to relieve the AIR of CHK1 (29, 30). Thus, the enhanced binding
to CDT2 observed with these CHK1 mutants is likely due to a
conformation change in CHK1 that relieves CHK1 autoinhibition
and exposes the CDT2 binding domain.
The accumulation of CDT2 was observed in HU-treated cells.
CDT2 accumulation in response to prolonged replication stress
was not observed when cells were treated with cycloheximide to
block new protein synthesis. This indicates that increases in CDT2
levels that accompany replication stress are due to enhanced tran-
scription and/or translation. Increases in CDT2 levels in HU-
treated cells correlated with an enhanced turnover of CHK1. This
finding indicates that changes in substrate receptor levels also con-
tribute to the enhanced turnover of certain substrates during
checkpoint activation. In the fission yeast Schizosaccharomyces
pombe, CDT2 levels also increase in response to HU treatment
(46).
Substrates of CRL4CDT2 are also often targeted to CRL1. For
example, the CUL1 substrate receptor SKP2 recruits CDT1, p21,
and SET8 to CRL1 for ubiquitination (54–56), and these sub-
strates are also regulated by CRL4CDT2. CDT1 has distinct binding
sites for each E3 ligase (57, 58). While CRL1SKP2 regulates CDT1
destruction in the S and G2 phases, CRL4
CDT2 regulates CDT1
destruction during DNA replication and in G1-phase cells with
DNA damage (57). CDT1 is ubiquitinated on chromatin by
CRL4CDT2 in a PCNA-dependent manner, whereas it is ubiquiti-
nated by the CRL1SKP2 complex in the nucleoplasm (24, 31,
33, 59).
We demonstrated that CRL1FBX6 and CRL4CDT2 target CHK1
in distinct subcellular locations, and we identified CRL4CDT2 as
the major E3 ligase targeting CHK1 for destruction during periods
of replication stress in HeLa cells. The replication stress-induced
phosphorylation of CHK1 occurs on chromatin, and the phos-
phorylated/activated from of CHK1 is then released from chro-
matin (4, 14), where it then phosphorylates effectors before being
degraded by CRL4CDT2. Thus, the regulation of substrate ubiquiti-
nation by distinct E3 ligases is determined by substrate receptors
and the subcellular compartmentalization of the substrate and
ligase and can be impacted by the phase of the cell cycle and
whether checkpoints have been activated or not.
The essential function of CHK1 in cell survival and early em-
bryonic development has been demonstrated by the constitutive
and tissue-specific deletion of CHK1 in mice (11, 60–63). How-
ever, a partial loss of CHK1 by hemizygous deletion was reported
previously to promote tumorigenesis and tumor progression in
the mouse mammary gland and skin (61, 64). Elevated expression
levels of CDT2 have been reported for several human cancers,
including hepatocellular carcinoma, breast and gastric cancers,
and Ewing sarcoma (65–68). The identification of CHK1 as a
CRL4CDT2 substrate may explain, in part, how CDT2 overexpres-
sion provides cancer cells with a proliferative advantage. By reduc-
ing CHK1 levels, CDT2 overexpression is expected to weaken
checkpoint barriers and enable cancer cells to progress through
the cell cycle in the presence of DNA damage.
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